Therapy Areas: Inflammatory Diseases
Longeveron secures US patent for stem cell therapy targeting aging-related frailty
12 November 2025 - American clinical-stage biotechnology company Longeveron Inc. (NASDAQ: LGVN) announced on Wednesday that it has received a new United States patent for its proprietary mesenchymal s...
ABIONYX Pharma advances strategic alliance talks with IHU SEPSIS to build global sepsis innovation platform
12 November 2025 - ABIONYX Pharma (Euronext Paris:ABNX), a biopharma company focused on breakthrough biotherapies to address life-threatening conditions with no effective treatments, announced on Wedn...
Mabwell receives NMPA approval to begin Phase II trial for IL-11-targeting drug for pathological scarring
11 November 2025 - Chinese biopharmaceutical company Mabwell Shanghai Bioscience Co Ltd (SHA: 688062) said on Tuesday that its novel anti-IL-11 monoclonal antibody, 9MW3811, has been approved by the C...
Vascarta and CUNY report positive preclinical results in glioblastoma treatment
11 November 2025 - Vascarta Inc, a clinical stage biopharmaceutical company developing therapies for pain, inflammation, and in collaboration with the City University of New York (CUNY), announced on ...
Akeso reveals preclinical research data for novel antagonistic monoclonal antibody aimed at IL-1RAP (AK135)
10 November 2025 - Akeso Inc (HKEX: 9926.HK), a China-based biopharmaceutical company, on Friday reported the preclinical research data for its novel antagonistic monoclonal antibody aimed at IL-1RAP,...
Sanofi and Regeneron's Dupixent meets all endpoints in pivotal AFRS study; sBLA accepted for FDA priority review
7 November 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) on Friday announced positive results from the phase 3 LIBERTY-AFRS-AIMS study evaluating Dupixent (dupilumab) ...